Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
President Trump has nominated Heidi Overton, a physician and deputy director of the White House Domestic Policy Council, to serve as the next FDA commissioner. Overton would inherit an agency rocked by mass layoffs, leadership turnover, and erratic policymaking since Marty Makary's resignation in May. Industry analysts are cautious, citing her limited drug regulatory experience and uncertainty about her impact on biopharma.
President Trump has nominated Heidi Overton — a physician, Johns Hopkins-trained surgeon, and current deputy director of the White House Domestic Policy Council — to be the next FDA commissioner. HHS Secretary Robert F. Kennedy Jr. announced the pick on X, with Bloomberg first reporting the decision. If confirmed by the Senate, Overton would take the helm of an agency that has been without a permanent leader since Marty Makary resigned in May.
The FDA has been in a state of upheaval during Trump's second term, marked by mass layoffs, high-level resignations, and what many in the industry described as unpredictable policymaking. Interim chief Kyle Diamantas has provided some stability, but Overton's nomination has raised questions given her lack of drug regulatory experience. She also appeared at a recent Oval Office signing of an executive order overhauling the childhood vaccine schedule.
Key Takeaways:
Why it matters: The FDA's stability is critical to U.S. drug development and public health. With the agency still reeling from leadership upheaval, Overton's confirmation — and her ability to restore predictability — will be closely watched by the pharmaceutical industry, investors, and patients alike.
